Recent events have illustrated the importance of developing new approaches to manufacturing technology for efficiently producing vaccines flexibly and at scale. MIT, together with Merck & Co., Repligen, and the University of Massachusetts Medical School, will use mechanistic modeling to design and construct a continuous vaccine manufacture process. Successful completion of this project will demonstrate the suitability of continuous manufacturing for vaccine production, with potentially transformative effects on supply chains and response times, along with improved product quality attributes.
- National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL)
- Massachusetts Life Science Center
- Merck & Co.
- University of Massachusetts Medical School